{"entity":{"id":"nct05147467","kind":"trial","name":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","aka":[],"tldr":"A phase 2 trial of APG2575 in chronic lymphocytic leukaemia, run by Ascentage Pharma Group Inc., now recruiting.","summary":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL is a phase 2 interventional study registered as NCT05147467 by Ascentage Pharma Group Inc., with 75 participants planned, started 2021-12-28 and due to reach its primary completion in 2026-12. Interventions recorded: APG2575.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05147467","url":"https://clinicaltrials.gov/study/NCT05147467"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ascentage-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05147467","phase":"2","setting":"A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","sponsor":"Ascentage Pharma Group Inc.","enrolled":75,"outcomes":[]},"route":"/trials/nct05147467/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"}]}}